Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid‐β peptide
暂无分享,去创建一个
B. Kriem | I. Sponne | A. Fifre | C. Malaplate-Armand | Karine Lozac’h-Pillot | V. Koziel | Frances T Yen-Potin | B. Bihain | T. Oster | J. Olivier | T. Pillot | C. Malaplate‐Armand
[1] E. Rogaev,et al. Molecular basis of Alzheimer’s disease , 2007, Molecular Biology.
[2] Á. Simonyi,et al. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. , 2004, Journal of lipid research.
[3] C. Leslie,et al. The calcium binding loops of the cytosolic phospholipase A2 C2 domain specify targeting to Golgi and ER in live cells. , 2003, Molecular biology of the cell.
[4] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[5] I. Sponne,et al. Apoptotic Neuronal Cell Death Induced by the Non-fibrillar Amyloid-β Peptide Proceeds through an Early Reactive Oxygen Species-dependent Cytoskeleton Perturbation* , 2003, The Journal of Biological Chemistry.
[6] W. Klein,et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta‐protein , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] M. Ball,et al. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down‐regulation and up‐regulation of apoptotic and pro‐inflammatory signaling , 2002, Journal of neuroscience research.
[8] D. Selkoe. Alzheimer's Disease Is a Synaptic Failure , 2002, Science.
[9] C. Leslie,et al. Inhibition of the MEK1/ERK pathway reduces arachidonic acid release independently of cPLA2 phosphorylation and translocation , 2002, BMC Biochemistry.
[10] T. Pillot,et al. The nonfibrillar amyloid beta-peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain. , 2002, Journal of neurochemistry.
[11] C. Funk,et al. Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.
[12] Q. Fan,et al. A Novel Action of Alzheimer's Amyloid β-Protein (Aβ): Oligomeric Aβ Promotes Lipid Release , 2001, The Journal of Neuroscience.
[13] S. Younkin,et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.
[14] J. Pettegrew,et al. Brain Membrane Phospholipid Alterations in Alzheimer's Disease , 2001, Neurochemical Research.
[15] N. Nishiyama,et al. Phospholipase A2 mediates ischemic injury in the hippocampus: a regional difference of neuronal vulnerability , 2001, The European journal of neuroscience.
[16] C. Finch,et al. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.
[17] P. Cohen,et al. Serine 727 Phosphorylation and Activation of Cytosolic Phospholipase A2 by MNK1-related Protein Kinases* , 2000, The Journal of Biological Chemistry.
[18] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[19] C. Masters,et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.
[20] G. Béréziat,et al. N-terminal and C-terminal plasma membrane anchoring modulate differently agonist-induced activation of cytosolic phospholipase A2. , 1999, European journal of biochemistry.
[21] L. Lue,et al. Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .
[22] D. Stephenson,et al. Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration , 1999, Glia.
[23] R. Nicoll,et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[24] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[25] S. Estus,et al. Aggregated Amyloid-β Protein Induces Cortical Neuronal Apoptosis and Concomitant “Apoptotic” Pattern of Gene Induction , 1997, The Journal of Neuroscience.
[26] C. Leslie. Properties and Regulation of Cytosolic Phospholipase A2 * , 1997, The Journal of Biological Chemistry.
[27] L. Horrocks,et al. Involvement of phospholipase A2 in neurodegeneration , 1997, Neurochemistry International.
[28] M. Cathcart,et al. Selective Inhibition of Cytosolic Phospholipase A2 in Activated Human Monocytes , 1997, The Journal of Biological Chemistry.
[29] D. Stephenson,et al. Cytosolic phospholipase A2 (cPLA2) and lipid mediator release in the brain. , 1996, Journal of lipid mediators and cell signalling.
[30] C. Cotman,et al. DNA damage and apoptosis in Alzheimer's disease: colocalization with c- Jun immunoreactivity, relationship to brain area, and effect of postmortem delay , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[31] D. Selkoe,et al. Cytosolic Phospholipase A2(cPLA2) Immunoreactivity Is Elevated in Alzheimer's Disease Brain , 1996, Neurobiology of Disease.
[32] William L. Smith,et al. Calcium-mediated Translocation of Cytosolic Phospholipase A2 to the Nuclear Envelope and Endoplasmic Reticulum (*) , 1995, The Journal of Biological Chemistry.
[33] S. Rapoport,et al. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain , 1995, Brain Research.
[34] L. Horrocks,et al. Neural membrane phospholipids in alzheimer disease , 1995, Neurochemical Research.
[35] D. Piomelli,et al. Dopamine D2 Receptors Potentiate Arachidonate Release via Activation of Cytosolic, Arachidonate‐Specific Phospholipase A2 , 1995, Journal of neurochemistry.
[36] J. Pettegrew,et al. Alzheimer's Disease: Membrane‐Associated Metabolic Changes a , 1994, Annals of the New York Academy of Sciences.
[37] T. Molski,et al. Cytoplasmic phospholipase A2 translocates to membrane fraction in human neutrophils activated by stimuli that phosphorylate mitogen-activated protein kinase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[38] M. V. Hogan,et al. Long-term potentiation in the hippocampus induced by platelet-activating factor , 1993, Neuron.
[39] Roger J. Davis,et al. cPLA2 is phosphorylated and activated by MAP kinase , 1993, Cell.
[40] J. D. Clark,et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP , 1991, Cell.
[41] C. Leslie,et al. A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7. , 1990, The Journal of biological chemistry.
[42] L. Lue,et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.
[43] L. Horrocks,et al. Elevated Activities of Lipases and Lysophospholipase in Alzheimer's Disease , 1990 .